Cargando…

Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates

Heterologous prime-boost immunization regimens are a common strategy for many vaccines. DNA prime rAd5-GP boost immunization has been demonstrated to protect non-human primates against a lethal challenge of Ebola virus, a pathogen that causes fatal hemorrhagic disease in humans. This protection corr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcus, Hadar, Thompson, Emily, Zhou, Yan, Bailey, Michael, Donaldson, Mitzi M., Stanley, Daphne A., Asiedu, Clement, Foulds, Kathryn E., Roederer, Mario, Moliva, Juan I., Sullivan, Nancy J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006325/ https://www.ncbi.nlm.nih.gov/pubmed/33790899 http://dx.doi.org/10.3389/fimmu.2021.627688

Ejemplares similares

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
por: Bolton, Diane L., et al.
Publicado: (2012)

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
por: Bart, P, et al.
Publicado: (2012)

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
por: Rouphael, Nadine G., et al.
Publicado: (2019)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost
por: Hutnick, NA, et al.
Publicado: (2012)

Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
por: Wang, Shixia, et al.
Publicado: (2017)

Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?
por: Pettini, Elena, et al.
Publicado: (2021)

Broad Protection of Pigs against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime/GP5-Mosaic rVaccinia (VACV) Vaccine Boost
por: Cui, Junru, et al.
Publicado: (2020)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

Hyperglycosylated gp120 mutants elicit improved CD4-binding site directed antibodies in a heterologous prime:boost regimen
por: Ahmed, FK, et al.
Publicado: (2012)

Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations
por: Pattani, Aditya, et al.
Publicado: (2012)

Prime-Boost Immunization of Rabbits with HIV-1 gp120 Elicits Potent Neutralization Activity against a Primary Viral Isolate
por: Narayan, Kristin M., et al.
Publicado: (2013)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants
por: Churchyard, Gavin, et al.
Publicado: (2016)

Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
por: Pasin, Chloé, et al.
Publicado: (2019)

Trans-saccadic priming in hemianopia: Sighted-field sensitivity is boosted by a blind-field prime
por: Ritchie, Kay L., et al.
Publicado: (2012)

Modeling the effect of boost timing in murine irradiated sporozoite prime-boost vaccines
por: Fernandez-Arias, Cristina, et al.
Publicado: (2018)

The immunogenicity and protective immunity of multi-epitopes DNA prime-protein boost vaccines encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis
por: Zhang, Jianhui, et al.
Publicado: (2020)

Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
por: Williams, WB, et al.
Publicado: (2012)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
por: Wille-Reece, Ulrike, et al.
Publicado: (2006)

Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant
por: Guenaga, Javier, et al.
Publicado: (2011)

Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen
por: Knudsen, Maria L., et al.
Publicado: (2015)

Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers
por: Sablerolles, Roos S G, et al.
Publicado: (2022)

Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice
por: Chapman, Rosamund, et al.
Publicado: (2013)

Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine
por: Tschismarov, Roland, et al.
Publicado: (2021)

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
por: Levine, Min Z., et al.
Publicado: (2019)

Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Immunogenicity of low dose prime-boost vaccination of mRNA vaccine CV07050101 in non-human primates
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
por: Logunov, Denis Y, et al.
Publicado: (2021)

Evaluation of the Potency of the Anti-Idiotypic Antibody Ab2/3H6 Mimicking gp41 as an HIV-1 Vaccine in a Rabbit Prime/Boost Study
por: Mader, Alexander, et al.
Publicado: (2012)

Correction: Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice
por: Chapman, Rosamund, et al.
Publicado: (2013)

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
por: Shen, Xiaoying, et al.
Publicado: (2020)

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
por: Venkatraman, Navin, et al.
Publicado: (2019)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

Seed Priming Boost Adaptation in Pea Plants under Drought Stress
por: Arafa, Sally A., et al.
Publicado: (2021)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_87vt2ninaaf9f0d9gis1q6p5tl